Several classes of aminoglycoside-modifying enzymes have been shown to confer bacterial resistance to the aminoglycoside amikacin: (i) AAC(6')-I, which is found in gram-negative organisms (16) ; (ii) AAC(6')-APH(2"), which is found in gram-positive organisms (11, 16) ; (iii) ANT(4',4")- I [also designated ANT(4')-I], which is also restricted to gram-positive bacteria (3, 16, 19) ; (iv) APH(3')-III, which is commonly found in gram-positive bacteria but has also been observed in Campylobacter spp. (10) ; and (v) APH(3')-VI, which is commonly associated with Acinetobacter spp. (9) . Recently, a novel amikacin resistance mechanism, ANT(4')-II, has been identified in a strain of Pseudomonas aeruginosa which carries the plasmid pMG77 (6) . This aminoglycoside adenylyltransferase confers resistance to amikacin, tobramycin, isepamicin, and other aminoglycosides with 4'-hydroxyl groups but not to dibekacin (6) . The ANT(4')-I enzyme, however, has been shown to modify aminoglycosides at both the 4' and 4" hydroxyl groups, and thus, dibekacin resistance is also conferred (19, 20) .
The ANT(4')-II aminoglycoside resistance profile (AGRP) was first detected in strains ofP. aeruginosa isolated in 1981, and by 1984, it was observed in isolates of Escherichia coli, Citrobacter spp., Klebsiella spp., and Serratia spp. (6) . Previous studies showed that clinical isolates with an ANT(4')-II AGRP failed to hybridize to a staphylococcal ant(4')-Ia probe (6) . These results suggested that the gene found in gram-positive bacteria was different from the gene encoding the enzyme observed in gram-negative bacteria (6) . In that study, a 1.6-kb DNA fragment was subcloned from pMG77, which carried the ant(4')-IIa gene. This study was initiated to determine the DNA sequence of the cloned P. Bacterial strains and plasmids. All bacterial strains and plasmids used in this study are listed in Table 1 . pBluescript II KS+ and pBluescript II SK+ are commercially available vectors (Stratagene, La Jolla, Calif.). The HindIII-EcoRI fragment of pMG235 (Table 1) was subcloned into pBluescript II KS+, generating pSCH3000. To reverse the orientation of the insert with respect to the lacZ promoter, the HindIII-EcoRI fragment from pSCH3000 was subcloned into pBluescript II SK+, which had been digested with HindIII- and MG1063 (Table 1) were transformed according to the method of Maniatis et al. (12) . Bacterial conjugations were performed in liquid medium (27) . Antibiotic concentrations for selections were as follows: ampicillin, 100 p,g/ml; tobramycin, 10 ,ug/ml; amikacin, 10 p,g/ml. MICs were determined by the microtiter dilution method as previously described (25) .
Preparation and analysis of DNA. Plasmid DNA was isolated from P. aeruginosa and E. coli by alkaline lysis for large-scale preparations (1) . Restriction enzyme digestions and ligations were performed according to the supplier's instructions (New England BioLabs). Restriction enzymegenerated DNA fragments were analyzed by agarose gel electrophoresis (0.7 to 2.5%) using Tris-borate-EDTA buffer (12) . Gamma-delta mutagenesis of the ant(4')-IIa gene. Gammadelta (TnlOOO) is an insertion element found on the E. coli F factor (5). This insertion element has been previously utilized for mutagenesis and localization of genes (21, 27) . The recA F+ E. coli strain MG1063 was transformed with pMG235 (Table 1) . Plasmid DNA was isolated from individual ampicillin-resistant, tobramycin-resistant transformants. The uncut DNA was analyzed by agarose gel electrophoresis to determine whether the transformants contained plasmids in multimeric or monomeric form. A single MG1063 transformant containing a monomeric form of pMG235 was mated to the streptomycin-resistant F-recipient strain C600. Transfer of the nonconjugative pMG235 to C600 resulted from mobilization of transient F--pMG235 cointegrates, whose formation was catalyzed by gamma-delta. The resolution of the cointegrate resulted in insertion of gamma-delta into the target plasmid. The mating mixture was plated on LB Schering agar containing 100 ,ug of streptomycin and 100 p,g of ampicillin per ml. Ampicillin-resistant, streptomycinresistant transconjugants were tested for susceptibility to 10 ptg of tobramycin per ml.
Nucleotide sequencing. The DNA sequence of the 1.6-kb insert of pMG235 was determined by using the dideoxy sequencing method (18) . DNA was isolated from seven pMG235 mutants containing gamma-delta insertions which inactivated the ant(4')-IIa gene. Sequenase 2.0 reactions were performed with primers homologous to the gammadelta transposon ends. Additional oligonucleotide primers (Research Genetics, Huntsville, Ala.) were used to extend the DNA sequence past the region covered by gamma-delta insertions. DNA fragments were resolved by electrophoresis on 6% polyacrylamide gels containing 8 M urea (12) . The gels were autoradiographed with XAR5 film (Eastman Kodak Co., Rochester, N.Y.).
Site-directed oligonucleotide mutagenesis. E. coli CJ236 carrying pSCH3000 was used to produce single-stranded DNA containing uracil by the method of McClary et al. (14) . Site-directed mutagenesis, in which a strong selection for the mutated strand is possible through the use of uracil-containing single-stranded DNA, was performed as previously described (8) . Oligonucleotides H8 and H9 ( Fig. 2 will appear in the EMBL, GenBank, and DDBJ nucleotide sequence data bases under the accession number M98270.
Nomenclature. The nomenclature for the aminoglycosidemodifying enzymes and the genes which encode them is as previously described (24) . Briefly, it is as follows: (i) type of enzymatic modification, i.e., AAC (acetyltransferase), ANT (nucleotidyltransferase or adenylyltransferase), or APH (phosphotransferase); (ii) site of modification, i.e., (1), (3), (6), (9), (2'), (3'), (4'), (6'), (2"), or (3"); (iii) unique resistance profile, i.e., I, II, III, IV, V, etc.; and (iv) unique protein designation, i.e., a, b, c, etc. The nomenclature of the genes which encode these enzymes is a modification of the genotype nomenclature of Mitsuhashi (17); e.g., aac(6')-Ia and aac(6')-Ib are unique genes encoding two proteins with the same resistance profile.
RESULTS
Localization of the ant(4')-IIa gene by gamma-delta mutagenesis. The F+ donor strain MG1063 carrying pMG235 was mated with C600 (Strr). Ampicillin-resistant, streptomycinresistant transconjugants were selected and tested for growth on plates containing 10 ,g of tobramycin per ml. Of 150 transconjugants, 26 were susceptible to tobramycin but resistant to streptomycin and ampicillin. These tobramycinsusceptible colonies were presumed to contain gamma-delta inserted into the ant(4')-IIa gene.
Detailed restriction analysis was performed on plasmid DNA isolated from eight tobramycin-susceptible transconjugants (pSCH3001 through pSCH3008) (Table 1 ) and the original plasmid, pMG235. Restriction maps of the plasmids were compared to determine locations of gamma-delta insertions within the 1.6-kb insert of pMG235. All of the insertions mapped within a 600-bp region (Fig. 1) .
DNA sequence analysis of the ant(4')-IIa gene. Analysis of the 1,271-bp region of pMG235, which contained the gammadelta insertions, revealed two large overlapping ORFs ( Fig. 1 and 2 ). The 5' noncoding region of ORF1 contains an inverted repeat from nucleotides 106 to 118 (stem 1) and 172 to 183 (stem 2) (Fig. 2) . The putative ATG start codon of ORFi is precisely centered within the 53-residue loop (Fig. 1) . This region may play a role in the expression of ORF1. However, no sequences with homology to the -35 and -10 consensus sequence recognized by the cr70 form of RNA polymerase were observed upstream of the start of ORFi (nucleotides 1 to 144) (Fig. 2) . A short potential ribosome-binding site, GAG, is located 7 nucleotides upstream of the predicted ATG start site of ORFi (Fig. 2) .
Comparison of the 1,271-bp sequence with the sequence of the ant(4')-Ia gene (13) showed no DNA homology. Comparison of this fragment with the GenBank DNA sequence library revealed that nucleotides 996 to 1271 were nearly identical to a region of DNA found flanking the aac(3)-IIIa gene (previously designated aacC3) from P. aeruginosa Travers (26) . In fact, the homology included the last 5 bp of the aac(3)-IIIa coding region. The region of identity encodes amino acids 21 through 92 of ORF3 as well as all of the DNA sequences downstream of ORF3 ( Fig. 1 and 2) .
The predicted amino acid sequence of the ant(4')-IIa gene was compared with the ANT(4')-Ia protein sequence (13) (Fig. 3) . Although the overall sequence identity was only 20%, the proteins were 69% similar and 38% identical when residues 38 to 63 of the ANT(4')-Ia protein were compared with residues 26 to 51 of the ANT(4')-IIa protein (Fig. 3) .
AGRP encoded by the ant(4')-IIa gene. Standard microdilution MIC testing was performed on P. aeruginosa SCH 84043005 and on E. coli DH5a transformants containing pMG235, pSCH3000, and pSCH3001 ( according to guidelines of the National Committee for Clinical Laboratory Standards and was also susceptible to dibekacin, 5-episisomicin, 2'-N-ethylnetilmicin, and 6'-Nethylnetilmicin (Table 3 ; also data not shown). E. coli DH5a carrying pMG235 showed a similar resistance profile, although lower MICs were observed (Table 3 ). E. coli DH5a/ pSCH3000, which contains the ant(4')-IIa gene subcloned into the high-copy-number vector pBluescript II KS+, showed slightly higher MICs. Expression of gamma-delta insertion mutant 1 (insertion point at nucleotide 195; Fig. 2 ) was also examined. E. coli DH5aIpSCH3001 was susceptible to all of the aminoglycosides tested, indicating that the resistance profile was completely abolished by gamma-delta insertion within the ant(4')-IIa gene (Table 3 , Fig. 1 ).
Plasmid pSCH3000 contains only 145 bp of DNA 5' of the putative ant(4')-IIa gene. In order to determine whether this region encoded the ant(4')-IIa promoter or whether the ant(4')-IIa gene was expressed from the lacZ promoter on the vector, the 1.6-kb insert was subcloned in the opposite orientation, resulting in pSCH3013. Nine independent transformants carrying pSCH3013 were streaked onto LB Schering agar containing 5, 10, 20, 25, or 30 ,ug of tobramycin per ml and compared with growth on 100-,ug/ml ampicillin plates. Growth was observed with all colonies on plates with ampicillin, demonstrating the presence of the plasmid in these strains. Growth of DH5alpSCH3000 was observed on plates containing <20 p,g of tobramycin per ml. However, colonies containing the same insert in the inverted orienta- Pseudomonas spp. tion with respect to the lacZ promoter did not grow at any concentration of tobramycin tested, suggesting that expression of the ant(4')-IIa gene from pSCH3000 and pMG235 in E. coli was from fortuitous vector promoters.
Northern blot analysis of the ant(4')-IIa coding region. RNA was isolated from E. coli DH5a and DH5oa/pMG235 and from P. aeruginosa SCH84043005, the strain from which the ant(4')-IIa gene was cloned. Each sample was run in a glyoxal-formaldehyde agarose gel (1) and blotted to GeneScreen Plus filters. The filters were hybridized with 32P-endlabeled oligonucleotides H9 and H10, which probed for ORFi and ORF2 mRNAs, respectively (Fig. 1 , Table 2 ). Oligonucleotide H10 did not hybridize to RNA from E. coli DH5a with or without pMG235, demonstrating that ORF2 RNA is not transcribed in E. coli (data not shown). Oligonucleotide H9 hybridized very strongly to RNA of -1,100
nucleotides from E. coli DH5a/pMG235 but did not hybridize to RNA from E. coli DH5a without the plasmid (data not shown). The size of the RNA was consistent with transcription initiation from the lacZ promoter 90 bp upstream of the HindIII site in pMG235. Since E. coli DH5o/pMG235 expresses an ANT(4')-II AGRP (Table 3 ) and since RNA is expressed only from ORF1, the data strongly suggest that ORFi encodes the ant(4')-IIa gene. The RNA from P. aeruginosa SCH84043005, which hybridized to H9 (ORFi), was -1,800 nucleotides, whereas the RNA which hybridized to H10 (ORF2) was more highly expressed and was -2,200 nucleotides (data not shown).
The data demonstrated that both ORFs were transcribed in P. aeruginosa. Oligonucleotide site-directed mutagenesis of the ant(4')-IIa gene. To demonstrate that ORFI does in fact encode the ant(4')-IIa gene, oligonucleotide H8 was used to convert the glycine codon in ORFi to the stop codon TGA (nucleotide 220) (Fig. 2) . On the opposite strand in ORF2, the single nucleotide alteration changed the TCC codon at this position to TCA, thereby maintaining a serine codon. A stop codon was similarly introduced in ORF2 at position 399 while retaining the serine codon in ORF1 at position 399 (Fig. 2) . Several of the mutations were confirmed by DNA sequence analysis. The KS primer (Table 2 ) and oligonucleotide Hll (Fig. 2, nucleotides 359 to 377) were utilized for sequencing the mutations. The DNA sequences of the two ORFi mutants showed the expected G-to-T change at position 220 (Fig. 2) . Similarly, six ORF2 mutants showed the expected G-to-A alteration at nucleotide 399 (Fig. 2) .
The ORF1 mutants were ampicillin resistant and tobramycin susceptible, suggesting that the stop codon introduced into ORF1 disrupted the function of the ant(4')-IIa gene. The ORF2 mutants still retained the ampicillin-resistant, tobramycin-resistant phenotype. These data demonstrated that ORF1 encodes the ant(4')-IIa gene and that ORF2 is not required for expression of the tobramycin-resistant phenotype in E. coli.
Development of an ant(4')-IIa probe. A 204-bp EcoRV-SspI fragment from the ant(4')-IIa gene (Fig. 2 ) was used as a probe to screen a battery of clinical isolates, which included (i) 92 gram-negative strains which had previously been identified by their AGRPs as ANT(4')-II; (ii) 9 Staphylococcus spp. identified by AGRP and DNA hybridization as carrying the ant(4')-Ia gene; and (iii) 21 strains, including Enterobacter cloacae, E. coli, Klebsiella spp., Providencia spp., Pseudomonas spp., Serratia spp., and Staphylococcus spp., which expressed a variety of other AGRPs. All of the strains listed above were also tested with a probe derived from the staphylococcal ant(4')-Ia gene ( Table 1) .
As expected, the nine Staphylococcus ANT(4')-I strains all hybridized to the ant(4')-Ia probe but did not hybridize to the ant(4')-IIa probe (Table 4 ). The 21 strains expressing other AGRPs did not hybridize to either probe (data not shown). Of the 92 strains identified as ANT(4')-II by AGRP, 85 hybridized to the ant(4')-IIa probe but did not hybridize to the ant(4')-Ia probe (Table 4) . It is important to note that all of the probe-positive strains were isolated from the Veterans Affairs (V.A.) Medical Center, Denver, Colo. Seven strains with an ANT(4')-II AGRP did not hybridize to either the ant(4')-IIa or the ant(4')-Ia probes, suggesting that at least one other unidentified ant(4') gene exists.
In a separate study (1Sa), resistance mechanisms were assigned to a collection of aminoglycoside-resistant organisms isolated between 1990 and 1991 on the basis of the AGRP of each strain. Of (6) . We determined the DNA sequence of 1,271 nucleotides of the 1.6-kb DNA fragment, which had been shown to encode the ant(4')-IIa gene (6) . Sequence analysis revealed three ORFs, two of which overlapped and were transcribed from opposite DNA strands.
ORF1 was shown by RNA analysis and through the introduction of a stop codon, which eliminated the expression of amikacin and tobramycin resistance, to encode the ant(4')-IIa structural gene. The ant(4')-IIa gene showed no homology with the ant(4')-Ia gene previously described (13) , which agrees with the failure to observe hybridization between an ant(4')-Ia probe and ANT(4')-II strains (6) .
The DNA sequence of the ant(4')-IIa gene predicted a 252-amino-acid protein of 28.9 kDa. The ANT(4')-IIa and ANT(4')-Ia proteins showed sequence conservation near the amino-terminal end. It is not clear whether this similarity is due to divergent or convergent evolution. The ANT(4')-IIa and ANT(4')-Ia proteins have previously been shown to differ in the spectrum of aminoglycoside modification (6, 19, 20) . Unlike the ANT(4')-II enzyme, the ANT(4')-I enzyme can also modify aminoglycosides, such as dibekacin, at the 4" hydroxyl position (19, 20 A DNA probe generated from a 204-bp ant(4')-IIa intragenic region was used to screen a collection of ANT(4')-I and ANT(4')-II strains. As expected, the probe did not hybridize to any of the ANT(4')-I strains. However, the majority (92%) of the ANT(4')-II strains, including most of the Citrobacterfreundii, E. cloacae, E. coli, Kiebsiella spp., Morganella spp., Pseudomonas spp., and Serratia spp. tested, hybridized to the ant(4')-IIa probe. All of the probepositive strains originated from the same hospital as the index strain. None of the five strains, which were classified as ANT(4')-II and originated from other hospitals, hybridized to this probe. In a larger study, only 7 of 4,228 aminoglycoside-resistant strains expressed an ANT(4')-II AGRP (15a) . These data show that organisms carrying an ANT(4')-II resistance profile were very rare and were almost always restricted to a single hospital. Strains isolated from the index hospital, which are characterized as ANT(4')-II, almost always carry the ant(4')-IIa gene, whereas strains which derive from other locales fail to hybridize to the probe. The presence of seven strains which expressed an ANT(4')-II profile but did not hybridize to either the ant(4')-Ia or the ant(4')-IIa probe suggested the existence of a third ant(4') gene in some gram-negative bacteria.
The ANT(4')-II AGRP was first observed in 1981 in a single strain of P. aeruginosa (6) . By 1984, this AGRP was observed in many strains of P. aeruginosa and in other gram-negative bacteria from the Denver V.A. hospital epidemic, including the P. aeruginosa strain from which the ant(4')-IIa gene was subsequently cloned (6) . Since the plasmid carrying the ant(4')-IIa gene in this P. aeruginosa strain had been identified as belonging to IncP-2 (7), a plasmid incompatibility group that is known to be limited to Pseudomonas species (7), its transfer from Pseudomonas strains to other members of the family Enterobacteriaceae in the Denver hospital must have been achieved by means other than whole-plasmid transfer. Mechanisms for dispersal include recombination with broad-host-range plasmids or association with transposons. Although this gene is associated with a single hospital, genetic selection through aminoglycoside usage may result in further dispersal of the ant(4')-IIa gene in gram-negative bacteria. ACKNOWLEDGMENTS pMG235 was kindly provided by G. Jacoby. E. coli MG1063 was a gift from C. M. Berg. We thank B. DiDomenico and D. Loebenberg for critical reading of the manuscript.
